Silvia Muro

Title: Innovations of Silvia Muro in Targeted Fusion Enzymes

Introduction

Silvia Muro is an accomplished inventor based in Gaithersburg, MD (US). She has made significant contributions to the field of biotechnology, particularly in the development of targeted fusion enzymes. With a total of three patents to her name, her work focuses on enhancing the delivery and efficacy of therapeutic proteins.

Latest Patents

Muro's latest patents revolve around ICAM-1 targeted fusion enzymes. These innovations involve proteins and nucleic acids that encode these proteins, which are designed to self-target to ICAM-1. The proteins can be enzymatically released at acidic pH, allowing for precise therapeutic applications. The ICAM-1-targeting peptides can be presented as single copies or multiple repeats, separated by linkers from the enzyme segment. This design enhances the activity of the enzyme segment, facilitating increased recognition and targeting of diseased organs. The proteins are capable of transporting from the bloodstream across the endothelium into diseased organs, promoting intracellular uptake and lysosomal trafficking in both peripheral tissues and the central nervous system. Muro's patents also include representative nucleotide and amino acid sequences, along with in vitro, cellular, and in vivo animal data, showcasing the potential of these proteins for use in protein therapy, gene therapy, or implanted cell therapy.

Career Highlights

Silvia Muro is affiliated with the University System of Maryland, where she continues to advance her research in targeted therapies. Her innovative work has positioned her as a leading figure in the field of biotechnology, contributing to the development of novel therapeutic strategies.

Collaborations

Muro collaborates with notable colleagues, including Jing Chen and Melani Solomon, who contribute to her research endeavors and enhance the impact of her work.

Conclusion

Silvia Muro's contributions to the field of biotechnology through her patents on ICAM-1 targeted fusion enzymes exemplify her commitment to advancing medical therapies. Her innovative approaches hold promise for improving treatment outcomes in various diseases.